
USD
( 0.00%
At Close (As of Jan 1, 1970)
$60.36M
Market Cap
0.687
P/E Ratio
6
EPS
$14.20
52 Week High
$2.64
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $5.9M |
| Total Revenue | $17M |
| Cost Of Revenue | $11M |
| Costof Goods And Services Sold | $11M |
| Operating Income | -$37M |
| Selling General And Administrative | $31M |
| Research And Development | $13M |
| Operating Expenses | $43M |
| Investment Income Net | - |
| Net Interest Income | -$607K |
| Interest Income | - |
| Interest Expense | $607K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $268K |
| Income Before Tax | -$37M |
| Income Tax Expense | $725K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$38M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$36M |
| Ebitda | -$36M |
| Net Income | -$38M |
| Field | Value (USD) |
|---|---|
| Total Assets | $60M |
| Total Current Assets | $35M |
| Cash And Cash Equivalents At Carrying Value | $25M |
| Cash And Short Term Investments | $25M |
| Inventory | $4.1M |
| Current Net Receivables | $4M |
| Total Non Current Assets | $25M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $6K |
| Intangible Assets Excluding Goodwill | $6K |
| Goodwill | $6.9M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $2.2M |
| Other Non Current Assets | - |
| Total Liabilities | $28M |
| Total Current Liabilities | $12M |
| Current Accounts Payable | $3M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $2.1M |
| Total Non Current Liabilities | $16M |
| Capital Lease Obligations | $4M |
| Long Term Debt | $8.9M |
| Current Long Term Debt | $1M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $14M |
| Other Current Liabilities | $6.3M |
| Other Non Current Liabilities | $4.5M |
| Total Shareholder Equity | $32M |
| Treasury Stock | - |
| Retained Earnings | -$295M |
| Common Stock | $1.5M |
| Common Stock Shares Outstanding | $13M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$22M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $268K |
| Capital Expenditures | $158K |
| Change In Receivables | - |
| Change In Inventory | $986K |
| Profit Loss | - |
| Cashflow From Investment | $146K |
| Cashflow From Financing | $37M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$38M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $5.9M |
| Total Revenue | $17M |
| Cost Of Revenue | $11M |
| Costof Goods And Services Sold | $11M |
| Operating Income | -$37M |
| Selling General And Administrative | $31M |
| Research And Development | $13M |
| Operating Expenses | $43M |
| Investment Income Net | - |
| Net Interest Income | -$607K |
| Interest Income | - |
| Interest Expense | $607K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $268K |
| Income Before Tax | -$37M |
| Income Tax Expense | $725K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$38M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$36M |
| Ebitda | -$36M |
| Net Income | -$38M |
| Field | Value |
|---|---|
| Ex Dividend Date | 2014-04-28 |
| Declaration Date | None |
| Record Date | None |
| Payment Date | None |
| Amount | 0.07 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Veru Inc. is a clinical-stage biopharmaceutical company headquartered in Miami, Florida, specializing in the development of innovative therapeutics for oncology and other unmet medical needs. The company's pipeline includes a range of drug candidates aimed at addressing various types of cancers, with a particular emphasis on both novel treatments and enhancements to existing therapies. Committed to advancing patient care, Veru leverages its proprietary technology and scientific expertise to bring potentially life-saving solutions to market while driving shareholder value.